Trial · NCT02110225
Outcomes16
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 16 of 16
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants With Serious and Non-Serious Adverse Events | up to 48 weeks | Safety population: all patients who received at least one dose of study medication. The safety population was used to analyze all safety endpoints (primary objective). | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Change in Ocular Tolerability - VAS | Weeks 1, 2, 6, 12, 24 | Safety population: patients who received at least one dose of study medication. The safety population was used to analyze all safety endpoints (primary objective). | units on a scale | MEAN |
| PRIMARY | Change in Best Corrected Distance Visual Acuity (BCDVA) (ETDRS Chart) | Weeks 1, 2, 6, 12, 24, 36, 48 | Safety population: patients who received at least one dose of study medication. The safety population was used to analyze all safety endpoints (primary objective). | Letters read correctly | MEAN |
| PRIMARY | Change in Intraocular Pressure (IOP) | Weeks 2,12 and 24 | Safety population: patients who received at least one dose of study medication. The safety population was used to analyze all safety endpoints (primary objective). | mmHg | MEAN |
| PRIMARY | Number of Participants With Normal or Abnormal Findings by Slit Lamp Examination | Day 0; Weeks 1, 2, 6, 12, 24, 36 and 48 | s | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | External Ocular Examination | Day 0, Weeks 1, 2, 6, 12, 24 | Safety population: all patients who received at least one dose of study medication. The safety population was used to analyze all safety endpoints (primary objective). | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Change in Ocular Tolerability - Dilated Fundus Ophthalmoscopy | Day 0, Weeks 12, 24 and 48 | Safety population: all patients who received at least one dose of study medication. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Presence of Anti-NGF Antibodies | At Day 0 and at week 24 | Safety population: all patients who received at least one dose of study medication. The safety population was used to analyze all safety endpoints (primary objective). | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Change From Baseline in Contrast Sensitivity | Weeks 12, 24, 36 and 48 | Intent to treat (ITT) population: all randomized patients. The ITT population was used for the exploratory analyses of ocular parameters. | score | MEAN |
| SECONDARY | Change From Baseline in Humphrey Visual Field 24-2 | Weeks 12, 24, 36 and 48 | Intent to treat (ITT) population: all randomized patients. The ITT population was used for the exploratory analyses of ocular parameters. | dB | MEAN |
| SECONDARY | Change in Goldmann Visual Field | Weeks 12, 24, 36 and 48 | Intent to treat (ITT) population: all randomized patients. The ITT population was used for the exploratory analyses of ocular parameters. | degrees | MEAN |
| SECONDARY | Fundus Imaging | Day 0, Weeks 24 and 48 | Intent to treat (ITT) population: all randomized patients. The ITT population was used for the exploratory analyses of ocular parameters. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Ocular Coherence Tomography (OCT) | Day 0, Weeks 12, 24, 36 and 48 | Intent to treat (ITT) population: all randomized patients. The ITT population was used for the exploratory analyses of ocular parameters. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Microperimetry | Day 0, Weeks 12, 24, 36 and 48 | Intent to treat (ITT) population: all randomized patients. The ITT population was used for the exploratory analyses of ocular parameters. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Binocular Estermann Visual Field | Day 0, Weeks 12, 24, 36 and 48 | Intent to treat (ITT) population: all randomized patients. The ITT population was used for the exploratory analyses of ocular parameters. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Electrorethinogram (ERG) | Day 0, Weeks 12, 24, 36 and 48 | Intent to treat (ITT) population: all randomized patients. The ITT population was used for the exploratory analyses of ocular parameters. | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02110225/outcomes